Novel function of bovine lactoferrin in lipid metabolism: Visceral fat reduction by enteric-coated lactoferrin

PharmaNutrition

Volumn 1, Issue 1, 2013, Pages 32-34

  Ono, Tomoji ^a,b   Morishita, Satoru ^a,c   Murakoshi, Michiaki ^a,d  

^a LION CORPORATION   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Enteric coating; Lactoferrin; Lipid metabolism; Visceral fat

Indexed keywords

CHOLESTEROL; GLUCOSE; LACTOFERRIN; PLACEBO; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOCHEMICAL COMPOSITION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; COLON CANCER; COLON POLYP; CONCENTRATION (PARAMETERS); DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG MEGADOSE; ENTERIC COATED TABLET; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOSTIMULATION; IN VITRO STUDY; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPID STORAGE; METABOLIC REGULATION; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION;

EID: 84877990109     PISSN: 22134344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phanu.2012.11.001     Document Type: Review

References (29)

1. Sørensen M., Sørensen S.P.L. The protein in whey. Comptes Rendus des Travaux du Laboratoire Carlsberg 1939, 23:55-99.
2. Metz-Boutigue M.H., Jollès J., Mazurier J., Schoentgen F., Legrand D., Spik G., et al. Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. European Journal of Biochemistry 1984, 145:659-676.
3. Anderson B.F., Baker H.M., Dodson E.J., Norris G.E., Rumball S.V., Waters J.M., et al. Structure of human lactoferrin at 3.2-A resolution. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:1769-1773.
4. Tomita M., Wakabayashi H., Shin K., Yamauchi K., Yaeshima T., Iwatsuki K. Twenty-five years of research on bovine lactoferrin applications. Biochimie 2009, 91:52-57.
5. Tomita M., Bellamy W., Takase M., Yamauchi K., Wakabayashi H., Kawase K. Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. Journal of Dairy Science 1991, 74:4137-4142.
6. Harmsen M.C., Swart P.J., de Béthune M.P., Pauwels R., De Clercq E., The T.H., et al. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. Journal of Infectious Diseases 1995, 172:380-388.
7. Zimecki M., Miedzybrodzki R., Szymaniec S. Oral treatment of rats with bovine lactoferrin inhibits carrageenan-induced inflammation; correlation with decreased cytokine production. Archivum Immunologiae et Therapiae Experimentalis 1998, 46:361-365.
8. Shoji H., Oguchi S., Shinohara K., Shimizu T., Yamashiro Y. Effects of iron-unsaturated human lactoferrin on hydrogen peroxide-induced oxidative damage in intestinal epithelial cells. Pediatric Research 2007, 61:89-92.
9. Sekine K., Ushida Y., Kuhara T., Iigo M., Baba-Toriyama H., Moore M.A., et al. Inhibition of initiation and early stage development of aberrant crypt foci and enhanced natural killer activity in male rats administered bovine lactoferrin concomitantly with azoxymethane. Cancer Letters 1997, 121:211-216.
10. Zou J., Dong J., Yu X.F. Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy. Helicobacter 2009, 14:119-127.
11. Nishino H., Satomi Y., Tokuda H., Masuda M. Cancer control by phytochemicals. Current Pharmaceutical Design 2007, 13:3394-3399.
12. Sekine K., Watanabe E., Nakamura J., Takasuka N., Kim D.J., Asamoto M., et al. Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Japanese Journal of Cancer Research 1997, 88:523-526.
13. Tsuda H., Sekine K., Nakamura J., Ushida Y., Kuhara T., Takasuka N., et al. Inhibition of azoxymethane initiated colon tumor and aberrant crypt foci development by bovine lactoferrin administration in F344 rats. Advances in Experimental Medicine and Biology 1998, 443:273-284.
14. Kozu T., Iinuma G., Ohashi Y., Saito Y., Akasu T., Saito D., et al. Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Preventive Research (Philadelphia) 2009, 2:975-983.
15. Wakabayashi H., Takase M., Tomita M. Lactoferricin derived from milk protein lactoferrin. Current Pharmaceutical Design 2003, 9:1277-1287.
16. Takeuchi T., Shimizu H., Ando K., Harada E. Bovine lactoferrin reduces plasma triacylglycerol and NEFA accompanied by decreased hepatic cholesterol and triacylglycerol contents in rodents. British Journal of Nutrition 2004, 91:533-538.
17. Tamano S., Sekine K., Takase M., Yamauchi K., Iigo M., Tsuda H. Lack of chronic oral toxicity of chemopreventive bovine lactoferrin in F344/DuCrj rats. Asian Pacific Journal of Cancer Prevention 2008, 9:313-316.
18. Pilvi T.K., Harala S., Korpela R., Mervaala E.M. Effects of high-calcium diets with different whey proteins on weight loss and weight regain in high-fat-fed C57BL/6J mice. British Journal of Nutrition 2009, 102:337-341.
19. Moreno-Navarrete J.M., Ortega F.J., Bassols J., Castro A., Ricart W., Fernández-Real J.M. Association of circulating lactoferrin concentration and 2 nonsynonymous LTF gene polymorphisms with dyslipidemia in men depends on glucose-tolerance status. Clinical Chemistry 2008, 54:301-309.
20. Moreno-Navarrete J.M., Ortega F.J., Bassols J., Ricart W., Fernández-Real J.M. Decreased circulating lactoferrin in insulin resistance and altered glucose tolerance as a possible marker of neutrophil dysfunction in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2009, 94:4036-4044.
21. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
22. Shimizu H. Development of an enteric-coated lactoferrin tablet and its application. Biometals 2004, 17:343-347.
23. Ono T., Murakoshi M., Suzuki N., Iida N., Ohdera M., Iigo M., et al. Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. British Journal of Nutrition 2010, 104:1688-1695.
24. Talukder M.J., Takeuchi T., Harada E. Characteristics of lactoferrin receptor in bovine intestine: higher binding activity to the epithelium overlying Peyer's patches. Journal of Veterinary Medicine A: Physiology, Pathology, Clinical Medicine 2003, 50:123-131.
25. Takeuchi T., Kitagawa H., Harada E. Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats. Experimental Physiology 2004, 89:263-270.
26. Hofmann S.M., Zhou L., Perez-Tilve D., Greer T., Grant E., Wancata L., et al. Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice. Journal of Clinical Investigation 2007, 117:3271-3282.
27. Ono T., Morishita S., Fujisaki C., Ohdera M., Murakoshi M., Iida N., et al. Effects of pepsin and trypsin on the anti-adipogenic action of lactoferrin against pre-adipocytes derived from rat mesenteric fat. British Journal of Nutrition 2011, 105:200-211.
28. Yagi M., Suzuki N., Takayama T., Arisue M., Kodama T., Yoda Y., et al. Lactoferrin suppress the adipogenic differentiation of MC3T3-G2/PA6 cells. Journal of Oral Science 2008, 50:419-425.
29. Moreno-Navarrete J.M., Ortega F.J., Ricart W., Fernandez-Real J.M. Lactoferrin increases (172Thr)AMPK phosphorylation and insulin-induced (p473Ser)AKT while impairing adipocyte differentiation. International Journal of Obesity (London) 2009, 33:991-1000.